SCHEMBL212663

SCHEMBL212663

COc1cc(NCc2ccc(C(=O)Nc3ccccc3N)cc2)c(C(=O)c2cc(OC)c(OC)c(OC)c2)cc1OC

nearest known ligand 0.74

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 20/20 0.74
HDAC2 Q92769 4/20 0.65
HDAC3 O15379 3/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
NCOR2 Q9Y618 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210074 0.90 HDAC1 (0.70) HDAC1HDAC2HDAC3HDAC7HDAC8
SCHEMBL1083659 0.87 HDAC1 (0.71) HDAC1HDAC2HDAC3NCOR2
SCHEMBL1061034 0.87 HDAC1 (0.71) HDAC1HDAC2HDAC3NCOR2
SCHEMBL1064968 0.85 HDAC1 (1.00) HDAC1HDAC2HDAC3HDAC6NCOR2
SCHEMBL2418799 0.83 HDAC1 (0.77) HDAC1HDAC2HDAC3HDAC7HDAC8
SCHEMBL1062997 0.82 HDAC1 (0.94) HDAC1HDAC2HDAC3NCOR2
SCHEMBL211241 0.82 NR1H4 (0.53) HDAC1HDAC2HDAC3HDAC7HDAC8
SCHEMBL1063625 0.81 HDAC1 (0.74) HDAC1HDAC2HDAC3HDAC7HDAC8
SCHEMBL1064455 0.81 HDAC1 (1.00) HDAC1HDAC2HDAC3HDAC7HDAC8
SCHEMBL10273123 0.81 LMNA (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 HDAC1 1/4885HDAC2 10/4885HDAC3 4/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 HDAC1 1/4885HDAC2 12/4885HDAC3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.